Herantis Pharma announces initiation of Phase 2 study for Lymfactin® gene therapy in secondary lymphedema


13.06.18 08:00
Meldung
 
Herantis Pharma announces initiation of Phase 2 study for Lymfactin® gene therapy in secondary lymphedema

Herantis Pharma announces initiation of Phase 2 study for Lymfactin® gene therapy in secondary lymphedema

Herantis Pharma Plc

Company release 13 Jun 2018 at 9:00 am

Herantis Pharma Plc ("Herantis") announced today the initiation of the Phase 2 clinical study AdeLE (Adenoviral gene therapy for the treatment of LE), which will evaluate the efficacy of Lymfactin® gene therapy in the treatment of secondary lymphedema (LE). The AdeLE study is a multicentre, randomized, double-blind, placebo-controlled study that intends to recruit 40 patients with breast cancer associated LE.  The main goal is to Analysethe therapeutic effect of Lymfactin® over placebo on improving the quality-of-life of patients, as well as reducing the swelling and other symptoms associated with the disease. Lymfactin is an adenovirus type 5-based gene therapy expressing human growth factor VEGF-C directly in the damaged tissue to promote the growth and repair of lymphatic vessels and restore the lymphatic network.

"The robust Phase 1 data, confirming safety and tolerability of Lymfactin®, favorably positioned us to quickly move into Phase 2 clinical evaluation, which is an important achievement for this program and the company," said Pekka Simula, Herantis' CEO. "Secondary lymphedema remains a disease with a noteworthy and underserved patient population and as a locally administered single dose therapy, Lymfactin® offers great potential to address this significant gap."

"At the moment there is no curative treatment for lymphedema. Lymfactin® stands out as a unique, easy-to-administer, and hopefully the first curative treatment option in a disease area where current therapies only relieve symptoms," added Anne Saarikko, MD, PhD, Principal Investigator of the study. "As such, we see the great potential of Lymfactin® and look forward to supporting the next step in terms of clinical development and further evaluation of this novel treatment."

The AdeLE study is now recruiting patients at Helsinki University Hospital, with Tampere and Turku University Hospitals (Finland) planned to join in June 2018. By the end of 2018, 2-3 additional hospitals in Sweden and Finland are planned to start enrolling patients.

About the AdeLE Study

AdeLE is a Phase 2 multi-center, randomized, double-blind, placebo-controlled study in patients with secondary lymphedema associated with the treatment of breast cancer. The study is planned to enrol 40 patients in Finland and Sweden and will assess the efficacy, safety and tolerability of a single dose of Lymfactin® compared to placebo in patients undergoing lymph node transfer surgery. Primary endpoints include volumetric measurements of the arm, quantitative lymphoscintigraphy, and quality-of-life assessment. To learn more, please visit http://herantis.com/lymfactin?lang=en.

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445

Company web site: www.herantis.com

Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225

About breast cancer associated lymphedema

Approximately 20% of breast cancer patients who undergo axillary lymph node dissection develop secondary lymphedema, a chronic, progressive, disabling and disfiguring disease that severely affects the quality of life. Symptoms include a chronic swelling of an upper limb, thickening and hardening of skin, loss of mobility and flexibility, pain, and susceptibility to secondary infections. Secondary lymphedema is currently treated with compression garments, special massage, and exercises. While these therapies may relief the symptoms in some patients they do not cure lymphedema, which is caused by damage to the lymphatic system. There are currently no approved medicines for the treatment of this disease.

About Lymfactin®

Lymfactin® is world's first and only clinical stage gene therapy that repairs damages of the lymphatic system. It expresses the human growth factor VEGF-C, which is natural and specific for the development of lymphatic vessels. Based on preclinical studies, Lymfactin® triggers the growth of new functional lymphatic vasculature in the damaged area and thus repairs the underlying cause of secondary lymphedema. Data from a Phase 1 clinical study in 15 patients with breast cancer associated LE suggest Lymfactin® is safe and well tolerated. The Phase 1 study continues with patient follow-up.

Lymfactin®, patented by Herantis, is based on the internationally renowned scientific research of academy professor Kari Alitalo and his research group, a national centre of excellence at the University of Helsinki. See an introductory video on Lymfactin®: http://herantis.com/media/videos/

About drug development in general

Drug development projects can usually be divided in two stages: The preclinical stage, and the clinical stage involving human subjects. The clinical stage can be further broken in three formal phases. Phase 1 clinical studies assess the safety of a drug candidate in human subjects. In Phase 2, the optimal dosing and possible efficacy in the treatment of a particular disease is studied. Phase 3 studies finally aim to establish a statistical proof of safety and efficacy of the drug candidate in typically hundreds or thousands of patients for market approval. Drug development can take 10-15 years from the first preclinical studies to market approval.

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson's disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Nasdaq Helsinki

Main media

www.herantis.com






This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Herantis Pharma Oyj via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

Herantis Pharma Ord Shs

Aktuelle Diskussionen zum Thema:

Herantis Pharma mit MK von ... (20.01.16)

Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Herantis Pharma Ord Shs
Weitere Meldungen
 
13.06 Ad hoc: HSBC Trinkaus & .
13.06 ING and AXA announce dig.
13.06 Herantis Pharma announces .
13.06 Sanofi : Sanofi successfully.
13.06 TiGenix announces a change.
13.06 WISeKey launches an Speci.
13.06 WISeKey to Present at the.
13.06 ERAMET Group: Offer for .
12.06 Ad hoc: Hawesko Holding A.
12.06 XPO Logistics Honors Driver.
12.06 Ad hoc: CO.DON AG: CO.D.
12.06 Ad hoc: mybet Holding SE .
12.06 Ad hoc: LS telcom AG: Be.
12.06 Orange Belgium increased it.
12.06 Pöyry PLC: Pöyry's pro for.
12.06 Ad hoc: Aladdin Blockchain .
12.06 Automotive company commit.
12.06 Volta Finance Limited : Earl.
12.06 KBC Group: Update regardin.
12.06 Ahold Delhaize share buybac.
12.06 Van Lanschot Kempen: upda.
12.06 ForFarmers N.V.: ForFarmer.
12.06 Santhera reicht Zulassungsan.
12.06 Santhera Submits NDA in S.
12.06 IMCD to acquire US specialt.
12.06 Ad hoc: PEH Wertpapier A.
11.06 Ad hoc: Solvesta AG: Aufs.
11.06 EQS-Adhoc: AEVIS VICTOR.
11.06 Ad hoc: SHS VIVEON AG:.
11.06 Ad hoc: Timeless Homes Gm.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 55392 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Der Preis für Kohlenstoff steigt drastisch, Quecksilber zieht ebenfalls an
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
Nel Asa, Nordex, Uber - ...
Feingold-Research, (24.08.19)
Experte: Feingold-Research,
Wenn der Bitcoin das ...
Robert Sasse, (24.08.19)
Experte: Robert Sasse,
Deutsche Bank: Super-...
RuMaS, (24.08.19)
Experte: RuMaS,
Evotec Aktie: Gelingt ...
Volker Gelfarth, (24.08.19)
Experte: Volker Gelfarth,
Goldman Sachs begibt ...
Börse Stuttgart AG, (24.08.19)
Experte: Börse Stuttgart AG,
Baisse an den ...
Claus Vogt, (24.08.19)
Experte: Claus Vogt,
Grüner: "Sorgen um das ...
Redaktion boerse-frankf., Deutsche Börse AG (24.08.19)
Experte: Redaktion boerse-frankfurt.de, Deutsche Börse AG
Chinas digitale Antwort auf ...
Frank Schäffler, (24.08.19)
Experte: Frank Schäffler,
Beiersdorf auf ...
Christian Lukas, volumen-analyse.de (24.08.19)
Experte: Christian Lukas, volumen-analyse.de
Welche Hürden der DAX ...
Sven Weisenhaus, Stockstreet GmbH (24.08.19)
Experte: Sven Weisenhaus, Stockstreet GmbH
Der Fluch der guten Tat
Bernd Niquet, Autor (24.08.19)
Experte: Bernd Niquet, Autor
Gold und Silber - Eng aber ...
Philip Hopf, Hopf Klinkmüller Capital. (23.08.19)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
Niquet's World
Neues vom Portal
 
Bitcoin Revolution: Erfahrung, Test und was aus 300€ Einzahlung wurde
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen